The U.S. Food and Drug Administration has approved Zepatier with or without ribavirin for the treatment of chronic Hepatitis C genotypes 1 and 4 infections in adult patients.
Tag Archive for: FDA
A network building capacity to prevent, manage and treat hepatitis B and C in NYC
Upcoming Events
Notice
There are no upcoming events.
News & Recent Posts
- Application | Harm Reduction Peer Academy @ Housing Works (Due January 30, 2025) January 10, 2026
- Job | INHSU Fellow January 6, 2026
- Job | Outreach Worker (Housing Works) December 22, 2025
- Funding | Hep B United Mini Grant (Deadline January 15, 2026) December 16, 2025
- Sign-On | Hep B United’s Statement on ACIP’s Hepatitis B Vaccine Votes (Deadline December 12) December 12, 2025
